Pancreatic Cancer: A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in
Adult Patients With Metastatic Pancreatic Adenocarcinoma (CanStem111P)
Will patients with pancreatic cancer have a longer cancer free survival when receiving
treatment with nab-Paclitaxel and Gemcitabine with the study drug, BBI-608, versus
treatment with nab-Paclitaxel and Gemcitabine alone?
Basic Study Information
Purpose:Location: Cancer Center
There will be two study groups: Group 1 (EXPERIMENTAL TREATMENT): Nab-Paclitaxel with
Gemcitabine plus BBI-608 and Group 2: (NON-EXPERIMENTAL TREATMENT): Nab-Paclitaxel
with Gemcitabine. Researchers are hoping to learn if patients will have a longer cancer
free survival when receiving a standard chemotherapy regimen with the study drug,
BBI-608 versus standard chemotherapy regimen alone.
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT02993731?term=CanStem111P&rank=1
Study Reference #: IGIP17029
Lead Researcher (Principal Investigator)
Lead Researcher: Marcus Noel
Study Contact InformationStudy Coordinator: Kari Steinmetz
Phone: (585) 276-4447
Additional Study Details
Learn More About These Conditions
More information about Pancreatic Cancer
Trial Not Found
The study you are looking for is not active at this time.
Return to Search